Nome Startup: M2TEST SRL
Sede: Italy, Trieste
Formata nel: 6/10/2016
(StartCup FVG, GIP Program Skydeck (Berkeley, CA), Miss In Action (Digital Magics-BNP Paribas), Tech Tour Final Contest (Essen, GE))
Fondatori: Francesca Cosmi, PhD, Inventor, more than 180 scientific publications;is a biomechanical engineer and the sole author of the first patent that is at the core of our product, and co-author of the subsequent patents. She has been developing the BES TEST project for over 10 years at the University of Trieste (where she is associate professor) before it become a real product. She has just started a two years sabbatical to be able to follow-up, as Senior Visiting Scientist, a large prospective trial that is in the design stage at the National Cancer Research Institute CRO in Aviano., Alessandra Nicolosi, CEO, PharmaD;is the co-author of the patents that are currently being deposited. She also has a strong interest in business administration issues: she has completed two acceleration program at Area Science Park in Trieste and successively at Digital Magics in Milan. She is currently representing our company at the Global Innovation Partner Program Fall 2019 Berkeley SkyDeck. Not only her scholar background complements Francesca’s one, but she is also her daughter and has been following this project since an early age. While there is a strong tradition of successful family business in Italy, it is true that in this specific case not only our competences complement each other perfectly but we can truly say that we know each other from a lifetime., Our third partner, by Innovation Factory srl, is the business incubator of Area Science Park and contributes to M2TEST as institutional partner through early stage investment and by giving access to Area Science Park services and network capabilities, as in this case, introducing us to SkyDeck.
M2TEST provides the BES TEST – Bone Elastic Structure Test: the next generation for osteoporosis diagnosis.
Our product, BES TEST , is an innovative test that assesses bone quality from a virtual biopsy of the patient. It is provided to healthcare specialists as SAAS (software as a service). It is based on a client-server architecture with cloud computing, which separates the imaging software from the one dedicated to computing and response generation.